lumiracoxib mod 19/ 2. 159 patienter (0, 88%) for NSAID, med et RF på 0, 79 [95% KI 0, 40- 1, 55] (ikke statistisk signifikant).
lumiracoxib versus 19/ 2159 patients (0.88%) for NSAIDs, with a HR of 0.79 [95% CI 0.40- 1.55] (not statistically significant).